No Ads. No Trackers. No Kidding! (Learn More)
After the FDA rejected Covaxin, Ocugen has almost no chance of generating profits from the shot. OCGN stock is a great short. [Read More]
Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at the... [Read More]
OCGN stock saw a glimmer of hope today. Where the company took a hit last week in deserting EUA, it is gaining today with a... [Read More]
Spokane-based pharmaceuticals manufacturer Jubilant HollisterStier has reached a deal to produce a new COVID-19 vaccine candidate for U.S. and Canadian markets. [Read More]
Ocugen said it is preparing to submit its application for approval for COVID-19 vaccine candidate Covaxin to the FDA soon. [Read More]
Ocugen (OCGN) to submit a BLA for its COVID-19 vaccine candidate, Covaxin, in the United States. The company will no longer pursue an EUA for... [Read More]
The company won't be getting emergency use authorization for Covaxin after all. [Read More]
Retail investors refuse to let OCGN stock die, even as the company makes it known that it wouldn't be applying for a crucial authorization. [Read More]
These prices are particularly surprising given that the phase 3 data for Covaxin have still not been published in a peer-reviewed scientific journal. [Read More]
Save As